User:Lan.wang17/Jon Zifferblatt

This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft.  Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL Easy tools: Citation bot (help) | Advanced: Fix bare URLs This page was last edited by [[User:|]] ([[User talk:|talk]] | contribs) 0 seconds ago. (Update timer) Finished writing a draft article? Are you ready to request an experienced editor review it for possible inclusion in Wikipedia? Save your work by pressing the "Publish page" button below, and a button will appear here allowing you to submit your draft for review.

Jon Zifferblatt MD/MPH/MBA, is healthcare professional and Editor-in-Chief of the China Pharmaceutical and Biotechnology Review. He is the managing director of General Biologic (GBI), a Shanghai-based consulting and data intelligence company^[1] and currently serves as the Vice Chair of the Shanghai American Chamber of Commerce- Healthcare Committee^[2]. Previously, Zifferblatt was the VP of ChinaVest, a merchant bank based in Shanghai. He received his B.S. education from Stanford and a MBA/MPH from University of Berkeley's Haas School of Business.^[3]

Zifferblatt frequently speaks and writes about China's pharmaceutical and healthcare space. He is a regularly contributor for the Pharmaceutical Executive magazine.^[4] Zifferblatt was also interviewed in Swedish newswire, Sydsvenskan, about the impact of China's healthcare reform.^[5]